- Home
- TGTX vs VNT Comparison
TGTX vs VNT Comparison
Compare TGTX & VNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TGTX
- VNT
- Stock Information
- Founded
- TGTX 1993
- VNT 2019
- Country
- TGTX United States
- VNT United States
- Employees
- TGTX N/A
- VNT N/A
- Industry
- TGTX Biotechnology: Pharmaceutical Preparations
- VNT Industrial Machinery/Components
- Sector
- TGTX Health Care
- VNT Industrials
- Exchange
- TGTX Nasdaq
- VNT Nasdaq
- Market Cap
- TGTX 5.5B
- VNT 6.2B
- IPO Year
- TGTX 1995
- VNT N/A
- Fundamental
- Price
- TGTX $33.65
- VNT $43.10
- Analyst Decision
- TGTX Strong Buy
- VNT Strong Buy
- Analyst Count
- TGTX 6
- VNT 8
- Target Price
- TGTX $47.50
- VNT $47.43
- AVG Volume (30 Days)
- TGTX 1.5M
- VNT 932.5K
- Earning Date
- TGTX 11-04-2025
- VNT 10-30-2025
- Dividend Yield
- TGTX N/A
- VNT 0.24%
- EPS Growth
- TGTX N/A
- VNT 1.28
- EPS
- TGTX 0.36
- VNT 2.63
- Revenue
- TGTX $454,069,000.00
- VNT $3,041,400,000.00
- Revenue This Year
- TGTX $82.13
- VNT $3.16
- Revenue Next Year
- TGTX $49.01
- VNT $5.30
- P/E Ratio
- TGTX $92.64
- VNT $16.05
- Revenue Growth
- TGTX 30.96
- VNT 1.16
- 52 Week Low
- TGTX $22.61
- VNT $27.22
- 52 Week High
- TGTX $46.48
- VNT $43.88
- Technical
- Relative Strength Index (RSI)
- TGTX 48.14
- VNT 59.22
- Support Level
- TGTX $34.01
- VNT $37.99
- Resistance Level
- TGTX $35.52
- VNT $43.71
- Average True Range (ATR)
- TGTX 1.28
- VNT 1.08
- MACD
- TGTX -0.24
- VNT 0.38
- Stochastic Oscillator
- TGTX 16.02
- VNT 88.72
About TGTX TG Therapeutics Inc.
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.
About VNT Vontier Corporation
Vontier, spun off from Fortive in 2020, is an industrial technology company with a portfolio of transportation and mobility solutions. The company offers a wide array of products and services, including fueling equipment, sensors, point-of-sale and payment systems, telematics, and equipment used by vehicle mechanics and technicians. Vontier generated approximately $3 billion in sales in 2024.